The OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Moderna reported better-than-expected 1Q24 revenue of $167 million and its pipeline looks promising. Read my earnings ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
マサチューセッツ州ケンブリッジ - Moderna, Inc. (NASDAQ:MRNA) は、60歳以上の成人における下気道疾患の予防を目的としたmRNA呼吸器合胞体ウイルス(RSV)ワクチン「mRESVIA」について、米国食品医薬品局(FDA)から承認を取得した。Moderna社のCOVID-19ワクチンと同じ ...
Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory ... A positive CDC decision from the agency will allow Moderna to compete in the U.S. fall ...
The US Food and Drug Administration approved Moderna’s respiratory syncytial virus (RSV ... had filed for FDA approval in July on data from a late-stage trial that showed its vaccine was ...
The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus, or RSV, got the green light from the FDA on Friday. It was approved to protect adults 60 years and older from lower ...
The drugmaker expects to have its vaccine for respiratory syncytial virus, or RSV, approved in the US this month. He speaks on "Bloomberg Surveillance." Vanishing Acts: 20 Hollywood Stars Who Faded ...